S100A1 and myocardial infarction: Using an anti-S100A1 antibody that was shown to prevent S100A1 internalization in CFs in vitro, we observed pro-inflammatory and pro-fibrotic effects in mice with neutralized S100A1 in experimental myocardial infarction, mirroring our in vitro results.